Logo image
Rheumatologic Medication Use During Pregnancy
Journal article   Peer reviewed

Rheumatologic Medication Use During Pregnancy

Emily A Peterson, Jessica Lynton, Allison Bernard, Mark K Santillan and Brittany Bettendorf
Obstetrics and gynecology (New York. 1953), Vol.135(5), pp.1161-1176
05/2020
DOI: 10.1097/AOG.0000000000003755
PMCID: PMC8928214
PMID: 32282595

View Online

Abstract

Chronic rheumatic diseases often occur in women of reproductive age, and the effect rheumatic disease has on pregnancy varies depending on the condition. Medical management of rheumatic diseases during pregnancy may prevent joint or organ damage and minimize the adverse effects of the disease itself on pregnancy outcomes. Each patient requires individual assessment to control disease activity while minimizing or avoiding medications with potential maternal or fetal toxicity. An open discussion with shared decision making between patients, obstetricians, rheumatologists, and pharmacists is imperative to create an individualized treatment plan that meets patients' goals. This article will review the current literature for use of disease modifying antirheumatic drugs and biologics during pregnancy and lactation, providing health care professionals with the most up-to-date information available.
Antirheumatic Agents - adverse effects Antirheumatic Agents - therapeutic use Breast Feeding Female Humans Lactation - drug effects Pregnancy Pregnancy Complications - drug therapy Pregnancy Outcome Rheumatic Diseases - drug therapy

Details

Metrics

Logo image